Combimatrix Corp (CBMX) 3.15 $CBMX CombiMatrix

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Combimatrix Corp (CBMX) 3.15 $CBMX

CombiMatrix Corporation to Release 2016 Second Quarter Financial Results on August 3, 2016
GlobeNewswire - Wed Jul 27, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX) announces that it will release financial results for the three and six months ended June 30, 2016 after market close on Wednesday, August 3, 2016. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
CBMX: 3.15 (-0.11)

CombiMatrix Launches Next Generation Sequencing for Pre-Implementation Genetic Screening
GlobeNewswire - Wed Jun 01, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, announces that it will begin accepting samples for pre-implantation genetic screening (PGS) by next generation sequencing (NGS) in mid-June.
CBMX: 3.15 (-0.11)

CombiMatrix to Present at Upcoming Investment Conferences
GlobeNewswire - Wed May 25, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, announces that that management will present at two upcoming investment conferences:
CBMX: 3.15 (-0.11)

CombiMatrix Comments on Additional Medical Policy Revisions to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue May 10, 5:44AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, noted that within the past two weeks the following managed care companies have revised their medical policies for genetic testing of fetal tissue as medically necessary for the evaluation of pregnancy loss in patients in specific cases. The revised medical policies state: "Genetic testing may be indicated (if desired by parents): In cases of pregnancy loss at 20 weeks of gestation or earlier when there is a maternal history of recurrent miscarriage (defined as a history of 2 or more failed pregnancies); or in all cases of pregnancy loss after 20 weeks of gestation."
CBMX: 3.15 (-0.11)

CombiMatrix Corporation Reports First Quarter 2016 Financial and Operating Results
GlobeNewswire - Wed May 04, 3:05PM CDT
Revenues Increase 28% to $3.0 Million on Record Reproductive Health
CBMX: 3.15 (-0.11)

CombiMatrix Corporation to Release 2016 First Quarter Financial Results on May 4, 2016
GlobeNewswire - Wed Apr 27, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX) announces that it will release financial results for the three months ended March 31, 2016 after market close on Wednesday, May 4, 2016. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
CBMX: 3.15 (-0.11)

CombiMatrix Notes Two Additional Blue Cross Blue Shield Health Plans Revise Medical Policies to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue Apr 26, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, notes that Blue Cross Blue Shield of Arkansas and Blue Cross Blue Shield of Tennessee have revised their medical policies to include reimbursement for chromosomal microarray analysis of fetal tissue for the evaluation of recurrent pregnancy loss. These health plans now cover cases of pregnancy loss at 20 weeks of gestation or earlier; or when there is a maternal history of recurrent miscarriage (defined as a history of two or more failed pregnancies).
CBMX: 3.15 (-0.11)

CombiMatrix Provides Strategic Update
GlobeNewswire - Thu Apr 21, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, has begun to explore strategic options including a range of potential M&A and business development opportunities to enhance shareholder value. As part of this effort, CombiMatrix has engaged Torreya Capital, a division of the Financial West Investment Group, Inc. ("Torreya", to advise the Company and its Board of Directors in this effort.
CBMX: 3.15 (-0.11)

CombiMatrix Comments on Medical Policy Revisions by Cigna Health and Three BCBS Health Plans to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue Mar 29, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that global health provider Cigna Health Services, Blue Cross Blue Shield of North Carolina, Premera Blue Cross Blue Shield and Life Wise of Oregon, an affiliate of Premera, have all revised their medical policies to include chromosomal microarray testing as medically necessary for the evaluation of recurrent pregnancy loss (i.e., two or more consecutive pregnancy losses). Since the beginning of 2016, six health plans have revised their medical policies to include coverage of recurrent pregnancy testing.
CBMX: 3.15 (-0.11)

CombiMatrix Closes $8.0 Million Underwritten Public Offering
GlobeNewswire - Thu Mar 24, 8:59AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, today announced that it has closed its previously announced firm commitment underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $8.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
CBMX: 3.15 (-0.11), LTS: 2.36 (-0.01)

ACOG and SMFM Update Practice Bulletins Recommending Prenatal Genetic Assessment for All Pregnant Women Regardless of Age or Other Risk Factors
GlobeNewswire - Wed Mar 23, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recently updated their practice bulletins recommending that all pregnant women regardless of age or other risk factors be offered prenatal assessment for aneuploidy and other genetic disorders. The updated information for prenatal testing was issued in Practice Bulletins "Prenatal Diagnostic Testing for Genetic Disorders" (Number 162, May 2016) and "Screening or Fetal Aneuploidy (Number 163, May 2016).
CBMX: 3.15 (-0.11)

CombiMatrix Prices $8.0 Million Underwritten Public Offering
GlobeNewswire - Mon Mar 21, 7:12AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, today announced that it has priced a firm commitment underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $8.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
CBMX: 3.15 (-0.11), LTS: 2.36 (-0.01)

CombiMatrix to Present at the ROTH Conference
GlobeNewswire - Wed Mar 09, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that President and Chief Executive Officer Mark McDonough will present a company overview at the 28 Annual ROTH Conference on Wednesday, March 16, 2016, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time). The conference is being held at The Ritz-Carlton, Laguna Niguel in Dana Point, Calif.
CBMX: 3.15 (-0.11)

CombiMatrix Migrates Miscarriage Analysis Microarray Testing to Newer Scanning Panel
GlobeNewswire - Tue Feb 09, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the migration of its microarray-based miscarriage testing to the Illumina HumanCytoSNP-12 BeadChip array platform. CombiMatrix had previously performed miscarriage analysis on the Illumina CytoSNP-850K BeadChip microarray platform.
CBMX: 3.15 (-0.11)

CombiMatrix Study Published in Genetics in Medicine
GlobeNewswire - Mon Feb 01, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the publication of data from a CombiMatrix study supporting the value of follow-up diagnostic testing to either confirm or rule out positive results for common chromosomal aneuploidies and microdeletion syndromes detected by non-invasive prenatal testing (NIPT).
CBMX: 3.15 (-0.11)

CombiMatrix Announces Commercial Launch of Microarray Testing for Stillbirth Analysis
GlobeNewswire - Thu Jan 28, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, announces the commercial launch of its SNP microarray genetic diagnostic testing for intrauterine fetal demise (IUFD), commonly known as stillbirth genetic testing.
CBMX: 3.15 (-0.11)

CombiMatrix Announces 1-for-15 Reverse Split of Common Stock
GlobeNewswire - Wed Jan 27, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, today announced stockholder approval of a reverse split of CombiMatrix Common Stock at a special meeting of stockholders.
CBMX: 3.15 (-0.11)

New Data From Multi-Year Study of Pregnancy Loss Support Efficacy and Diagnostic Power of CombiMatrix's Chromosomal Microarray Analysis
GlobeNewswire - Wed Jan 06, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, announces that new data from a multi-year study support the efficacy of SNP-based chromosomal microarray analysis (CMA) in detecting chromosomal imbalances. Data from the study conducted by CombiMatrix will be presented by Trilochan Sahoo, M.D., FACMG, the company's Vice President of Clinical Affairs and Director of Cytogenetics, at the World Congress on Recurrent Pregnancy Loss in Cannes, France on January 16, 2016.
CBMX: 3.15 (-0.11)

CombiMatrix Announces Multicycle Offering for Pre-Implantation Genetic Screening and Improved Cost Efficiencies
GlobeNewswire - Wed Dec 16, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis, postnatal developmental disorders, and pre-implantation genetic screening (PGS) services, today announced that it has launched its PGS Multicycle Program. The PGS Multicycle Program provides patients the flexibility of testing eight embryos over the course of 12 months for a one-time payment. CombiMatrix is the pioneer in per-embryo pricing in conjunction with PGS testing. With the addition of a multicycle PGS option, CombiMatrix continues to offer the most flexible, cost-effective solutions for patients while increasing the upfront cash payments received for genetic testing services.
CBMX: 3.15 (-0.11)

CombiMatrix Highlights Two Recent Developments
GlobeNewswire - Fri Dec 11, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, today highlighted two recent developments.
CBMX: 3.15 (-0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading